Fideuram Intesa Sanpaolo Private Banking S.P.A. Buys New Stake in Bruker Corporation $BRKR

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Bruker Corporation (NASDAQ:BRKR) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 482,859 shares of the medical research company’s stock, valued at approximately $17,441,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd purchased a new position in shares of Bruker during the 2nd quarter valued at about $192,735,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after buying an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC grew its holdings in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the period. Franklin Resources Inc. grew its holdings in Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Millennium Management LLC raised its position in Bruker by 222.6% during the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after acquiring an additional 1,269,316 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Performance

Shares of BRKR stock opened at $61.64 on Friday. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54. The business’s 50 day moving average is $50.13 and its two-hundred day moving average is $44.90. The company has a market capitalization of $9.38 billion, a P/E ratio of -256.83, a P/E/G ratio of 1.94 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the company posted $0.47 EPS. The business’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio is currently -83.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BRKR shares. Wolfe Research began coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. UBS Group set a $60.00 target price on shares of Bruker in a report on Wednesday, June 24th. Citigroup boosted their target price on shares of Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $54.54.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.